415 related articles for article (PubMed ID: 18050743)
1. [Cationic liposomes loaded with doxorubicin targeting to the tumor neovasculature in vitro].
Zhao W; Ma HL; Qi XR
Yao Xue Xue Bao; 2007 Sep; 42(9):982-8. PubMed ID: 18050743
[TBL] [Abstract][Full Text] [Related]
2. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
3. Cationic liposome (DC-Chol/DOPE=1:2) and a modified ethanol injection method to prepare liposomes, increased gene expression.
Maitani Y; Igarashi S; Sato M; Hattori Y
Int J Pharm; 2007 Sep; 342(1-2):33-9. PubMed ID: 17566677
[TBL] [Abstract][Full Text] [Related]
4. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model.
Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ
Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073
[TBL] [Abstract][Full Text] [Related]
5. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
[TBL] [Abstract][Full Text] [Related]
6. The influence of size, lipid composition and bilayer fluidity of cationic liposomes on the transfection efficiency of nanolipoplexes.
Ramezani M; Khoshhamdam M; Dehshahri A; Malaekeh-Nikouei B
Colloids Surf B Biointerfaces; 2009 Aug; 72(1):1-5. PubMed ID: 19395245
[TBL] [Abstract][Full Text] [Related]
7. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
9. [Preparation of cationic liposomes and its role in enhancing cellular uptake of antisense oligonucleotides].
Chen HL; Liang WQ; Shao JB; Chen Z
Yao Xue Xue Bao; 2004 Jan; 39(1):72-6. PubMed ID: 15127587
[TBL] [Abstract][Full Text] [Related]
10. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
Yu JM; Li YJ; Qiu LY; Jin Y
J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
[TBL] [Abstract][Full Text] [Related]
11. Anionic amino acid-derived cationic lipid for siRNA delivery.
Suh MS; Shim G; Lee HY; Han SE; Yu YH; Choi Y; Kim K; Kwon IC; Weon KY; Kim YB; Oh YK
J Control Release; 2009 Dec; 140(3):268-76. PubMed ID: 19567256
[TBL] [Abstract][Full Text] [Related]
12. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
13. DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery.
Zhang Y; Li H; Sun J; Gao J; Liu W; Li B; Guo Y; Chen J
Int J Pharm; 2010 May; 390(2):198-207. PubMed ID: 20116418
[TBL] [Abstract][Full Text] [Related]
14. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.
Ishida T; Okada Y; Kobayashi T; Kiwada H
Int J Pharm; 2006 Feb; 309(1-2):94-100. PubMed ID: 16364578
[TBL] [Abstract][Full Text] [Related]
15. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
[TBL] [Abstract][Full Text] [Related]
17. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
18. PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells.
Dai W; Yang T; Wang X; Wang J; Zhang X; Zhang Q
J Drug Target; 2010 May; 18(4):254-63. PubMed ID: 19824864
[TBL] [Abstract][Full Text] [Related]
19. The use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors.
Szala S; Missol E; Sochanik A; Strozyk M
Gene Ther; 1996 Nov; 3(11):1026-31. PubMed ID: 9044744
[TBL] [Abstract][Full Text] [Related]
20. A physicochemical characterization of the interaction between DC-Chol/DOPE cationic liposomes and DNA.
RodrÃguez-Pulido A; Ortega F; Llorca O; Aicart E; Junquera E
J Phys Chem B; 2008 Oct; 112(39):12555-65. PubMed ID: 18729499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
